Comparative Pharmacology
Head-to-head clinical analysis: ERYC SPRINKLES versus ZMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC SPRINKLES versus ZMAX.
ERYC SPRINKLES vs ZMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptidyl-tRNA. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
Azithromycin, the active ingredient in ZMAX, is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
250-500 mg orally every 6 hours (or 333 mg every 8 hours) for adults; maximum 4 g/day.
500 mg orally once daily, administered as a single dose on an empty stomach.
None Documented
None Documented
1.5-2.0 hours in adults with normal renal function; prolonged in neonates (2-4 hours) and patients with hepatic impairment.
Terminal half-life: 68 hours (range 40-80 h); prolonged in hepatic impairment (up to 120 h) and elderly; supports once-weekly dosing.
Primarily biliary (fecal) elimination (60-80% as unchanged drug) with approximately 5-15% renal excretion of active drug.
Renal: ~20% unchanged; fecal: ~50% as metabolites; biliary: ~30% as metabolites and parent drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic